Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

Todd Neale

June 27, 2017

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

Advertisement

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Need a Statin for Primary Prevention? There’s an App for That

LDL Control Remains Poor in CAD Patients: NHANES

Vast Majority of HFrEF Patients Eligible for Vericiguat

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Could an App Replace Statin Prescribing by Doctors?

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Evolocumab Not Cost-Effective at Current List Price

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content